Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/29/2015)... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial ... quarter of 2015, the Company reported a net loss of $24.0 ... of $13.4 million, or $0.18 loss per share, for the same ... the Company reported a net loss of $25.2 million, or $0.30 ... or $0.35 loss per share, for the first half of last ...
(Date:7/29/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today ... 2015 financial results after the market closes on Wednesday, ... by a conference call at 5:00 p.m. ET, which ... webcast. During the conference call, the company will review ... The conference call dial-in numbers are (877) ...
(Date:7/29/2015)... Calif., July 29, 2015  Depomed, Inc. (Nasdaq: ... achievements for the quarter ended June 30, 2015. ... the pain and neurology marketplace, with significant net product ... substantial value to our shareholders in both the immediate ... of Depomed. "Growth in the second quarter was led ...
Breaking Medicine Technology:Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 3Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 4Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 5Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 6Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 7Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 8Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 9Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 10Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 11Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 12Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 13Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 14Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 15
... Beginning April 1, Highmark Blue Cross Blue Shield ... with primary immunodeficiency diseases and other rare disorders to ... (IgG - a blood plasma product), regardless of their ... patients who are being treated successfully with another brand ...
... ANGELES, March 21, 2011 Attorneys from Dallas, Heygood, Orr ... that will require executives from Watson Pharmaceuticals Inc. (NYSE: ... oath and produce key documents as part of a lawsuit over ... company,s fentanyl patch. Attorney Michael Heygood represents ...
Cached Medicine Technology:Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases 2Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases 3Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit 2
(Date:7/30/2015)... ... July 30, 2015 , ... Summer is the dry ... Add to that a particularly long, dry and hot 2015 summer season and the ... fresh water advocate Sharon Kleyne will discuss the 2015 summer season and identify the ...
(Date:7/30/2015)... ... July 30, 2015 , ... The renowned Brain ... its history of funding brain aneurysm research. , Each year, the Brain ... toward scientific research directed at early detection, improved treatment modalities, and technological advances ...
(Date:7/30/2015)... ... ... PeopleKeys, a company with over 30 years of experience in behavioral analysis, today ... newest installment in their popular DISC for the Real World series, will air at ... is intended for people interested in training others to use DISC behavioral analysis as ...
(Date:7/29/2015)... ... , ... Drs. Hamstead are very excited to announce the expansion of ... in the clinic; massage therapy works very well alongside chiropractic care to restore balance ... AlignLife of Simpsonville to work alongside the doctors. Many people can benefit from massage ...
(Date:7/29/2015)... Los Angeles, CA (PRWEB) , ... July 29, 2015 , ... According to an ... published by the National Institutes of Health shows exactly what a person needs to do ... sex, height, and weight, the app will give informed estimates as to the number of ...
Breaking Medicine News(10 mins):Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2Health News:AlignLife of Simpsonville Hires Massage Therapist 2Health News:New NIH Body Weight Planner Illustrates the Need for Reduced Caloric Intake When Trying to Lose Weight, Says Beverly Hills Physicians 2
... Help Kids Worldwide, NEW YORK, Feb. 4 ... are being asked to submit creative,drawings for the 2008 ... One winner will be chosen from thousands of,entries and ... UNICEF,holiday greeting card, sold exclusively at Pier 1 Imports ...
... YORK, February 4, 2008 The Juvenile Diabetes ... of type 1 diabetes research, announced today that ... company based in Winston-Salem, N.C. that focuses on ... Through its Industry Discovery and Development Partnership Program, ...
... Feb. 4 Renowned esthetician, Karen,Dunlap, has developed ... recognized as the number-one most nutritious and powerful ... the dots between science and,nature, Dunlap discovered that ... -- magnifies its benefits. Her new signature facial, ...
... and 4 percent of former illicit drug users ... year following an organ transplant. These results are ... a journal by John Wiley & Sons. The ... ( http://www.interscience.wiley.com/journal/livertransplantation ). , Substance abuse can lead ...
... 2008 Contrary to previous research, older adults who use ... reduced risk of developing dementia or Alzheimers disease. This is ... the American Geriatrics Society that tracked patients using vitamin E ... than 5 years. The study also finds that the combined ...
... connecting patients and caregivers offers tips to families, ... ... helpful, CHICAGO, Feb. 4 What do you say, what ... or suffering from a serious,disease? To kick-off National Patient Recognition Week, ...
Cached Medicine News:Health News:Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest 2Health News:Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest 3Health News:JDRF partners with Plureon to explore generating insulin-producing cells from adult stem cells 2Health News:Breakthrough 'Acai Berry Anti-Aging Facial' Applies Benefits of Nature's Super-Food to the Skin 2Health News:Former substance abusers rarely relapse after organ transplantation 2Health News:Vitamin E or C does not reduce risk of dementia or Alzheimer's 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 2Health News:It's National Patient Recognition Week - Here's How You Can Do Something Special for Someone Facing Illness 3
... Stryker Universal Wedge Screw is ... in cruciate reconstruction and is ... BTB grafts. The Universal Wedge ... and has blunt threads which ...
... combination of a screw and a barbed pin. ... resorbable pins for a hammertoe fixation and prevents ... use! Drill and tap the proximal phalanx. Drill ... the implant proximally. Press fit the barbed portion ...
The Stryker Graft Workstation offers the surgeon flexibility in graft preparation. The posts are interchangeable and the system adapts to both soft tissue and bone grafts selection. Sizing gauges off...
... The Stryker Conquest Suture ... instruments that pierce through ... suture through the tissue ... The Conquest Retrievers are ...
Medicine Products: